Efficacy and safety of TACE combined with traditional Chinese medicine versus TACE alone in hepatocellular carcinoma: bayesian network meta-analysis and pharmacological mechanisms study

被引:0
|
作者
Chen, Li [1 ,2 ]
Zhu, Xiu-Ling [2 ]
Lin, Jie [3 ]
Li, Dong-Liang [1 ,2 ]
机构
[1] Fujian Med Univ, Fuzong Clin Med Coll, Dept Hepatobiliary Dis, Fuzhou, Fujian, Peoples R China
[2] 900 Hosp Joint Logist Team Chinese PLA, Dept Hepatobiliary Dis, Fuzhou, Fujian, Peoples R China
[3] Jilin Univ, Affiliated Hosp 2, Dept Hepatobiliary & Pancreat Surg, Changchun, Jilin, Peoples R China
关键词
hepatocellular carcinoma; transarterial chemoembolization; traditional Chinese medicine; bayesian network meta-analysis; network pharmacology; molecular docking;
D O I
10.3389/fphar.2024.1495343
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: This study investigates the clinical benefits of integrating traditional Chinese medicine (TCM) with Transarterial Chemoembolization (TACE) in hepatocellular carcinoma (HCC) treatment via meta-analysis and an exploration of network pharmacology analysis (NPA). Methods: A comprehensive search across different databases retrieved all randomized controlled trials (RCTs) evaluating TCM combined with TACE for HCC. Meta-analysis included 39 RCTs to assess the intervention effects. The bayesian network meta-analysis observed the relative efficacy and potential ranking of various interventions. Active compounds and target genes from frequently used TCM were sourced from the TCMSP database, while HCC disease targets were collected from five public disease databases. Regulatory networks connecting target genes with active components of key herbs were constructed. Following the identification of key genes, we conducted analyses of Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) to enrich our understanding of their functions. NPA and molecular docking methods were refined to reveal potential interactions between TCM components and their specific targets. Results: The combination of TCM with TACE significantly enhances the efficacy and safety of HCC treatment, improving the overall response rate, disease control rate, and overall survival rate, while also reducing the incidence of adverse events. Among the TCM evaluated, Ganfu Formula proved to be the most effective in enhancing patient response rates. Analysis of all included medicinal herbs identified 10 pivotal TCMs and 17 core genes. GO analysis revealed their significance in protein interactions, whereas KEGG analysis highlighted their role in crucial oncological pathways. NPA and molecular docking techniques elucidate the underlying mechanisms of action of TCM components. Conclusion: Adding TCM to TACE protocols significantly enhances treatment outcomes and safety in HCC patients by modulating tumor biology and systemic immune responses, highlighting its potential as an effective adjunct therapy. These findings support the inclusion of TCM in standard care regimens, offering potential for improved management of HCC.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] The efficacy and safety of Apatinib combined with TACE in the treatment of hepatocellular carcinoma: a meta-analysis
    Anan Gong
    Xiaofei Li
    World Journal of Surgical Oncology, 20
  • [2] The efficacy and safety of Apatinib combined with TACE in the treatment of hepatocellular carcinoma: a meta-analysis
    Gong, Anan
    Li, Xiaofei
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2022, 20 (01)
  • [3] Efficacy and safety of camrelizumab combined with TACE for hepatocellular carcinoma: a systematic review and meta-analysis
    Xian, F.
    Song, X. -W.
    Bie, J.
    Zhao, C. -X.
    Zhang, G. -J.
    Xu, G. -H.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2024, 28 (02) : 687 - 701
  • [4] TACE combined with PEI versus TACE alone in the treatment of HCC: a meta-analysis
    Wang, Na
    Guan, Quanlin
    Wang, Kai
    Zhu, Bingdong
    Yuan, Wenzhen
    Zhao, Peng
    Wang, Xiaowei
    Zhao, Yongxun
    MEDICAL ONCOLOGY, 2011, 28 (04) : 1038 - 1043
  • [5] TACE combined with PEI versus TACE alone in the treatment of HCC: a meta-analysis
    Na Wang
    Quanlin Guan
    Kai Wang
    Bingdong Zhu
    Wenzhen Yuan
    Peng Zhao
    Xiaowei Wang
    Yongxun Zhao
    Medical Oncology, 2011, 28 : 1038 - 1043
  • [6] Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis
    Zou, Jing Huai
    Zhang, Lan
    Ren, Zheng Gang
    Ye, Sheng Long
    JOURNAL OF DIGESTIVE DISEASES, 2016, 17 (08) : 510 - 517
  • [7] TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study
    Tang, Zhihong
    Bai, Tao
    Wei, Tao
    Wang, Xiaobo
    Chen, Jie
    Ye, Jiazhou
    Li, Shangqi
    Wei, Meng
    Li, Xingzhi
    Lin, Youzhi
    Tang, Juan
    Li, Lequn
    Wu, Feixiang
    BMC CANCER, 2024, 24 (01)
  • [8] Efficacy and Safety of TACE Combined with Regorafenib versus TACE Combined with Camrelizumab in Hepatocellular Carcinoma With Untreatable Progression After TACE Combined with Sorafenib Therapy: A Case Control Study
    Ren, Yanqiao
    Liu, Yiming
    Song, Songlin
    Zheng, Chuansheng
    CANCER CONTROL, 2024, 31
  • [9] Integration of meta-analysis and network pharmacology analysis to investigate the pharmacological mechanisms of traditional Chinese medicine in the treatment of hepatocellular carcinoma
    Lin, Jie
    Guo, Huaijuan
    Qin, Hanjiao
    Zhang, Xuewen
    Sheng, Jiyao
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [10] Efficacy and safety analysis of TACE + Donafenib + Toripalimab versus TACE + Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study
    Haohao Lu
    Bin Liang
    Xiangwen Xia
    Chuansheng Zheng
    BMC Cancer, 23